PROTECTIVE IMMUNE RESPONSES AGAINST HEPATITIS C VIRUS

描述(改编自申请人摘要)：全球，1.7亿人 慢性感染丙型肝炎病毒(丙型肝炎)。一种保险箱的开发 而有效的丙型肝炎病毒重组亚单位疫苗是我们的长期目标。 由于对病毒包膜蛋白的体液反应的质量和 细胞对多种丙型肝炎病毒蛋白反应的广度影响疾病 决议，丙型肝炎疫苗必须由多个丙型肝炎病毒蛋白和 利用一种能引起广泛免疫的策略。这是可行的 在第一阶段的研究中展示了这种方法，生产了五个 病毒结构蛋白。这些蛋白质似乎具有天然的结构， 每种疫苗都有特定的属性，这使它们作为亚单位疫苗具有吸引力 候选人。在第二阶段的研究中，将生产更多的丙型肝炎病毒蛋白。老鼠 将用单独的和组合的蛋白质免疫，并且 体液反应的组成和细胞的程度和类型 我们将对收到的回复进行评估。通过解剖免疫反应，一个 可以定义疫苗策略，使每个亚单位的潜力最大化。在……里面 在第二阶段研究的最后一年，确定的疫苗战略将是 在灵长类动物身上进行了测试。第二阶段研究产生的信息代表 开发抗丙型肝炎病毒多组分疫苗的关键一步。 建议的商业应用：不可用

DESCRIPTION (Adapted from Applicant's Abstract): Worldwide, 170 million people are chronically infected with Hepatitis C virus (HCV). Development of a safe and efficacious recombinant subunit vaccine for HCV is our long-term goal. Since the quality of the humoral response to viral envelop proteins and the breadth of the cellular response to multiple HCV proteins influence disease resolution, an HCV vaccine must be comprised of multiple HCV proteins and utilize a strategy which elicits broad based immunity. Feasibility of this approach was demonstrated in Phase I research within the production of five viral structural proteins. These proteins appear to have native-like structure, and each has specific attributes which make them attractive as subunit vaccine candidates. In Phase II research additional HCV proteins will be produced. Mice will be immunized with individual and combinations of proteins, and the composition of the humoral response and the extent and type of cellular response elicited will be evaluated. By dissecting the immune response, a vaccine strategy can be defined which maximizes each subunit's potential. In the last year of Phase II research, the identified vaccine strategy will be tested in primates. The information generated from Phase II research represents a crucial step in developing a multi-component vaccine against HCV. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE